PURPOSE: Breast cancer epidemiology and survival recently saw major changes resulting from improved screening and treatment modalities. This paper aims to provide an overview of changes in recent years in patient characteristics and treatment procedures. METHODS: Using data from BRENDA, an unselected cohort with universal coverage of a constant catchment area over a 13-year observation period, this study provides an overview of key trends. RESULTS: Beside steady increases in overall and disease-free survival, main trends in recent years included a gradual increase in new patients' average ages. Grading, but not T stages, improved. Node negative, endocrine responsive patient shares increased; node positive, endocrine responsive shares decreased. HER2neu screening went from uncommon to ubiquitous. Sentinel node biopsy reduced excised numbers of lymph nodes. Second and third generation chemotherapies replaced CMF. Neoadjuvant therapy was gradually introduced. Aromatase inhibitors pushed down Tamoxifen use. 90 % of endocrine responsive patients now receive endocrine therapy. Our results suggest that improved survival only partially results from improved prognostic factors, but rather seems mainly due to improved treatment modalities. CONCLUSIONS: Treatment procedures have changed dramatically over recent years. This was associated with steady increases in favorable outcomes among patients.
PURPOSE:Breast cancer epidemiology and survival recently saw major changes resulting from improved screening and treatment modalities. This paper aims to provide an overview of changes in recent years in patient characteristics and treatment procedures. METHODS: Using data from BRENDA, an unselected cohort with universal coverage of a constant catchment area over a 13-year observation period, this study provides an overview of key trends. RESULTS: Beside steady increases in overall and disease-free survival, main trends in recent years included a gradual increase in new patients' average ages. Grading, but not T stages, improved. Node negative, endocrine responsive patient shares increased; node positive, endocrine responsive shares decreased. HER2neu screening went from uncommon to ubiquitous. Sentinel node biopsy reduced excised numbers of lymph nodes. Second and third generation chemotherapies replaced CMF. Neoadjuvant therapy was gradually introduced. Aromatase inhibitors pushed down Tamoxifen use. 90 % of endocrine responsive patients now receive endocrine therapy. Our results suggest that improved survival only partially results from improved prognostic factors, but rather seems mainly due to improved treatment modalities. CONCLUSIONS: Treatment procedures have changed dramatically over recent years. This was associated with steady increases in favorable outcomes among patients.
Authors: Christian Felix Reibold; Wakuma Tariku; Pia Eber-Schulz; Sefonias Getachew; Adamu Addisie; Susanne Unverzagt; Andreas Wienke; Steffen Hauptmann; Claudia Wickenhauser; Martina Vetter; Ahmedin Jemal; Christoph Thomssen; Eva Johanna Kantelhardt Journal: Breast Care (Basel) Date: 2021-01-15 Impact factor: 2.860
Authors: A-M Grumpelt; A Ignatov; S N Tchaikovski; E Burger; S-D Costa; H Eggemann Journal: J Cancer Res Clin Oncol Date: 2016-01-25 Impact factor: 4.553
Authors: Lukas Schwentner; Reyn Van Ewijk; Thorsten Kühn; Felix Flock; Riccardo Felberbaum; Maria Blettner; Rolf Kreienberg; Wolfgang Janni; Achim Wöckel; Susanne Singer Journal: Support Care Cancer Date: 2016-01-27 Impact factor: 3.603
Authors: Eva Lorenz; Maria Blettner; Björn Lange; Marcus Schmidt; Astrid Schneider; Lukas Schwentner; Daniel Wollschläger; Hiltrud Merzenich Journal: Breast Care (Basel) Date: 2018-03-29 Impact factor: 2.860
Authors: E C Inwald; M Koller; M Klinkhammer-Schalke; F Zeman; F Hofstädter; P Lindberg; M Gerstenhauer; S Schüler; O Treeck; O Ortmann Journal: J Cancer Res Clin Oncol Date: 2015-08-08 Impact factor: 4.553